Engineered for Ocular Innovation

Key Attributes of the Hydrogel Platform

Our hydrogel technology is a versatile platform employed to create sustained-release therapies that may expand treatment options across multiple ocular conditions.

The hydrogel delivery technology enables the use of drugs that are known to be safe and efficacious when formulated as drops or injections by creating sustained release dosage forms.

Sustained Release Drug Delivery

Our proprietary hydrogel platform is engineered to create soft, biocompatible drug therapeutics that provide sustained and localized drug delivery.1, 2-4 Localized delivery facilitates targeted transmission of the drug to provide therapy and minimizes systemic exposure.2,5

The hydrogel is a biodegradable polyethylene glycol (PEG)1 network and is preservative free. This hydrogel network is a meshwork that entraps the drug particles. When administered the PEG network hydrates with water, then the drug particles begin to dissolve, diffusing the drug outward from the hydrogel into the surrounding local tissues.1 Following the completion of drug delivery, the hydrogel biodegrades and is cleared from the body.2

The company’s novel technology can be formulated to provide sustained release from days6 to months3,4 depending on the treatment required. The versatile hydrogel platform can be used to deliver both small molecules7 and large proteins at both small and large molecular weights.8

Applications of the Hydrogel Technology

References: 1. Sawhney AS, Jarrett P, Bassett M, Blizzard C, inventors; Incept, LLC, assignee. Drug delivery through hydrogel plugs. US patent 8,409,606 B2. April 2, 2013. 2. Lee A, Blair HA. Dexamethasone Intracanalicular Insert: A Review in Treating Post-Surgical Ocular Pain and Inflammation. Drugs. 2020;80(11):1101-1108. 3. Boyer DS, Wong J, Chang A, et al. Evaluating Safety, Tolerability and Biological Activity of OTX-TKI, a Hydrogel-Based, Sustained-Release Intravitreal Axitinib Implant, in Subjects with Neovascular Age-Related Macular Degeneration. Presented at the American Academy of Ophthalmology Annual Meeting; Virtual; November 13-15, 2020. Goldstein MH, Goldberg D, Walters TR, Vantipalli S, Braun E, Metzinger JL. Evaluating Safety, Tolerability and Efficacy of an Intracameral Hydrogel-Based Travoprost Implant in Subjects with Glaucoma – Phase 1 Trial. Invest Ophthalmol Vis Sci. 2020;61(7):4266. 5. Mundell L, Lindemann R, Douglas J. Monitoring long-term oral corticosteroids. BMJ Open Qual. 2017;6(2):e000209. 6.Gira JP, Sampson R, Silverstein SM, Walters TR, Metzinger JL, Talamo JH. Evaluating the patient experience after implantation of a 0.4 mg sustained release dexamethasone intracanalicular insert (Dextenza): results of a qualitative survey. Patient Prefer Adherence. 2017;11:487-494. 7. Tyson SL, Bafna S, Gira JP, et al. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2019;45(2):204-212. 8. Elhayek RF, Jarrett PK, Sawhney A, et al. Pharmacokinetics of Bevacizumab Sustained Release from Intravitreal Hydrogel Depots in a Rabbit Model Compared to a single Avastin Dose. Invest Ophthalmol Vis Sci. 2015;56(7):1522.